Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® for Familial Chylomicronemia Syndrome in China
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Forte Minerals Corp Exhibits at PDAC 2026, Highlighting the Alto Ruri Project's High-Grade Potential Near Barrick's Pierina Mine
NextSource Materials Announces Closing of $25 Million LIFE Offering to Advance UAE Battery Anode Facility
Canadian Securities Exchange Approves Gold Runner Exploration's Option to Acquire the Golden Girl Property from the B-ALL Syndicate in British Columbia's Prolific Golden Triangle
